Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men
-
Luboslav Stárka
Abstract
Evidence has been accumulating that 7-hydroxyepimers of dehydroepiandrosterone may act as locally active immunomodulatory and immunoprotective agents, counteracting the actions of glucocorticoids. 7α- and 7β-hydroxylated metabolites of dehydroepiandrosterone are present in near nanomolar concentrations in human blood. Limited data have been available on its changes during the last decades of human life. We examined 213 healthy Central European males in age groups from 50 to 91years and determined both 7-hydroxyepimers, 7α- and 7β-hydroxy-dehydroepiandrosterone, in sera using specific radioimmunoassays. The age dependence of steroid levels was evaluated using one-way ANOVA. In men, a distinct decline in 7α-hydroxy-dehydroepiandrosterone with age was observed. The curves for age dependence of 7-hydroxy metabolite levels in males resembled those previously determined for unconjugated dehydroepiandrosterone. The levels of both 7-hydroxylated epimers correlated excellently with each other.
References
1. Šulcová J, Hampl R, Hill M, Stárka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J Endocrinol 1997; 154:57–62.10.1677/joe.0.1540057Search in Google Scholar PubMed
2. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999; 39:327–48.10.1177/00912709922007903Search in Google Scholar PubMed
3. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 2004; 151:1–14.10.1530/eje.0.1510001Search in Google Scholar PubMed
4. Beck SG, Handa RJ. Dehydroepiandrosterone (DHEA): a misunderstood adrenal hormone and spine-tingling neurosteroid? Endocrinology 2004; 145:1039–41.10.1210/en.2003-1703Search in Google Scholar PubMed
5. Legrain S, Girard L. Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects. Drugs Aging 2003; 20:949–67.10.2165/00002512-200320130-00001Search in Google Scholar PubMed
6. Hinson JP, Brooke A, Raven PW. Therapeutic uses of dehydroepiandrosterone. Curr Opin Invest Drugs 2003; 4:1205–8.Search in Google Scholar
7. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 2003; 6:151–6.10.1080/tam.6.3.151.156Search in Google Scholar
8. Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 2003; 3:635–41.10.1016/j.coph.2003.07.006Search in Google Scholar PubMed
9. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003; 21:346–55.10.1007/s00345-003-0367-7Search in Google Scholar PubMed
10. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004; 3:171–87.10.1016/j.arr.2003.05.001Search in Google Scholar PubMed
11. Morfin R, Lafaye P, Cotillon AC, Nato F, Chmielewski V, Pompon D. 7-α-Hydroxy-dehydroepiandrosterone and immune response. Ann NY Acad Sci 2000; 917:971–82.10.1111/j.1749-6632.2000.tb05464.xSearch in Google Scholar PubMed
12. Pelissier MA, Trap C, Malewiak MI, Morfin R. Antioxidant effects of dehydroepiandrosterone and 7α-hydroxy-dehydroepiandrosterone in the rat colon, intestine and liver. Steroids 2004; 69:137–44.10.1016/j.steroids.2003.12.006Search in Google Scholar
13. Morfin R, Stárka L. Neurosteroid 7-hydroxylation products in the brain. Int Rev Neurobiol 2001; 46:79–95.10.1016/S0074-7742(01)46059-4Search in Google Scholar
14. Akwa Y, Young J, Kabbadj K, Sancho MJ, Zucman D, Vourc'h C, et al. Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. J Steroid Biochem Mol Biol 1991; 40:71–81.10.1016/0960-0760(91)90169-6Search in Google Scholar
15. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003; 5:197–234.Search in Google Scholar
16. Robinzon B, Michael KK, Ripp SL, Winters SJ, Prough RA. Glucocorticoids inhibit interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandrosterone: a role for 11β-hydroxysteroid dehydrogenases? Arch Biochem Biophys 2003; 412:251–8.10.1016/S0003-9861(03)00056-0Search in Google Scholar
17. Hampl R, Hill M, Stárka L. 7-Hydroxydehydroepiandrosterone epimers in the life span. J Steroid Biochem Mol Biol 2001; 78:367–72.10.1016/S0960-0760(01)00108-XSearch in Google Scholar
18. Lapčík O, Hampl R, Hill M, Bičíková M, Stárka L. Immunoassay of 7-hydroxysteroids: 1. Radioimmunoassay of 7α-hydroxydehydroepiandrosterone. J Steroid Biochem Mol Biol 1998; 67:439–45.Search in Google Scholar
19. Lapčík O, Hampl R, Hill M, Stárka L. Immunoassay of 7-hydroxysteroids: 2. Radioimunoassay of 7α-hydroxy-dehydroepiandrosterone. J Steroid Biochem Mol Biol 1999; 71:231–7.10.1016/S0960-0760(99)00145-4Search in Google Scholar
20. Hanuš M, Matoušková M, Hill M, Stárka L. Hormonal homeostasis in a group of 216 ageing Czech males and correlation with responses to a questionnaire of the University of St. Louis. Age Aging 2005;8. In press.10.1080/13685530600624150Search in Google Scholar
21. Stárka L, Kůtová J. 7-Hydroxylation of dehydroepiandrosterone by rat liver homogenate. Biochim Biophys Acta 1962; 36:76–82.10.1016/0006-3002(62)90528-0Search in Google Scholar
22. Hampl R. Morfin R, Stárka L. 7-Hydroxylated derivatives of dehydroepiandrosterone: what are they good for? Endocr Regul 1997; 31:211–8.Search in Google Scholar
23. Lathe R. Steroid and sterol 7-hydroxylation: ancient pathways. Steroids 2002; 67:967–77.10.1016/S0039-128X(02)00044-2Search in Google Scholar
24. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W. Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 1994; 31:99–104.10.1007/BF00925945Search in Google Scholar PubMed
25. Chmielewski V, Drupt F, Morfin R. Dexamethasone induced apoptosis of mouse thymocytes: prevention by native 7α-hydroxysteroids. Immunol Cell Biol 2000; 78:238–46.10.1046/j.1440-1711.2000.00905.xSearch in Google Scholar
26. Starka L, Hill M, Hampl R, Malewiak, Benalycherif A, Morfin R, et al. Studies on the mechanism of antiglucocorticoid action of 7α-hydroxydehydroepiandrosterone. Collect Czech Chem Commun 1998; 63:1683–98.10.1135/cccc19981683Search in Google Scholar
27. Lafaye P, Chmielewski V, Nato F, Mazié J-C, Morfin, R. The 7α-hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens. Biochim. Biophys Acta 1999; 1472:222–31.10.1016/S0304-4165(99)00124-5Search in Google Scholar
28. Khalil MW, Strutt B, Vachon D, Killinger DW. Effect of dexamethasone and cytochrome P450 inhibitors on the formation of 7α-hydroxydehydroepiandrosterone by human adipose stromal cells. J Steroid Biochem Mol Biol 1994; 48:545–52.10.1016/0960-0760(94)90206-2Search in Google Scholar
29. Akwa Y, Sananes N, Gouezou M, Robel P, Baulieu EE, Le Goascogne C. Astrocytes and neurosteroids: metabolism of pregnenolone and dehydroepiandrosterone. Regulation by cell density. J Cell Biol 1993; 121:135–43.10.1083/jcb.121.1.135Search in Google Scholar
30. Muller C, Cluzeaud F, Pinon GM, Rafestin-Oblin ME, Morfin R. Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor. J Steroid Biochem Mol Biol 2004; 92:469–76.10.1016/j.jsbmb.2004.10.014Search in Google Scholar
31. Strömstedt M, Warner M, Banner CD, MacDonald PC, Gustafsson JA. Role of brain cytochrome P450 in regulation of the level of anesthetic steroids in the brain. Mol Pharmacol 1993; 44:1077–83.Search in Google Scholar
32. Jellinck PH, Lee SJ, McEwen BS. Metabolism of dehydroepiandrosterone by rat hippocampal cells in culture: possible role of aromatization and 7-hydroxylation in neuroprotection. J Steroid Biochem Mol Biol 2001; 78:313–7.10.1016/S0960-0760(01)00106-6Search in Google Scholar
33. Pringle AK, Schmidt W, Deans JK, Wulfert E, Reymann KG, Sundstrom LE. 7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro. Eur J Neurosci 2003; 18:117–24.10.1046/j.1460-9568.2003.02734.xSearch in Google Scholar
34. Yau JL, Rasmuson S, Andrew R, Graham M, Noble J, Olsson T, et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 2003; 121:307–14.10.1016/S0306-4522(03)00438-XSearch in Google Scholar
35. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99:13589–94.10.1073/pnas.162477299Search in Google Scholar PubMed PubMed Central
36. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Schumacher M, Delacourte A, et al. In vitro metabolism of dehydroepiandrosterone (DHEA) to 7α-hydroxy-DHEA and δ5-androstene-3β,17β-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Res 2003; 969:117–25.10.1016/S0006-8993(03)02288-1Search in Google Scholar
37. Bičíková M, Řípová D, Hill M, Jirák R, Havlíková H, Tallová J, et al. Plasma levels of 7-hydroxylated dehydroepiandrosterone (DHEA) metabolites and selected amino-thiols as discriminatory tools of Alzheimer's disease and vascular dementia. Clin Chem Lab Med 2004; 42:518–24.10.1515/CCLM.2004.088Search in Google Scholar PubMed
38. Attal-Khemis S, Dalmeyda V, Michot JL, Roudier M, Morfin R. Increased total 7α-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1998; 53:B125–32.10.1093/gerona/53A.2.B125Search in Google Scholar
39. Kim SB, Hill M, Kwak YT, Hampl R, Jo DH, Morfin R. Neurosteroids: cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab 2003; 88:5199–206.10.1210/jc.2003-030646Search in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region
- Isotretinoin therapy induces DNA oxidative damage
- Structural evaluation of plasma α2-macroglobulin in acute pancreatitis
- Failure of the PAXgene™ Blood RNA System to maintain mRNA stability in whole blood
- Reticulocyte hemoglobin measurement – comparison of two methods in the diagnosis of iron-restricted erythropoiesis
- Physical analysis of ejaculate to evaluate the secretory activity of the seminal vesicles and prostate
- Specificity of the 3H-triolein assay for pancreatic lipase in blood plasma
- Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice
- Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men
- Prevalence of abnormal thyroid stimulating hormone and thyroid peroxidase antibody-positive results in a population of pregnant women in the Samara region of the Russian Federation
- Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum
- Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis
- Mean and variance quality control for multiple correlated levels of replicated control samples
- Clinical evaluation of serodiagnosis of active tuberculosis by multiple-antigen ELISA using lipids from Mycobacterium bovis BCG Tokyo 172
- Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010
- Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult
- Deficient α-galactosidase A activity in plasma but no Fabry disease – a pitfall in diagnosis
- Reportable interval of patient examination results and ISO 15189
Articles in the same Issue
- Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region
- Isotretinoin therapy induces DNA oxidative damage
- Structural evaluation of plasma α2-macroglobulin in acute pancreatitis
- Failure of the PAXgene™ Blood RNA System to maintain mRNA stability in whole blood
- Reticulocyte hemoglobin measurement – comparison of two methods in the diagnosis of iron-restricted erythropoiesis
- Physical analysis of ejaculate to evaluate the secretory activity of the seminal vesicles and prostate
- Specificity of the 3H-triolein assay for pancreatic lipase in blood plasma
- Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice
- Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men
- Prevalence of abnormal thyroid stimulating hormone and thyroid peroxidase antibody-positive results in a population of pregnant women in the Samara region of the Russian Federation
- Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum
- Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis
- Mean and variance quality control for multiple correlated levels of replicated control samples
- Clinical evaluation of serodiagnosis of active tuberculosis by multiple-antigen ELISA using lipids from Mycobacterium bovis BCG Tokyo 172
- Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010
- Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult
- Deficient α-galactosidase A activity in plasma but no Fabry disease – a pitfall in diagnosis
- Reportable interval of patient examination results and ISO 15189
